Function Health Medical Leadership and Credentials: An Independent Review

Who Leads Function Health Medically?

Function Health's most recognizable clinical figurehead is Dr. Mark Hyman, MD. He trained in family medicine and is a longtime faculty member at the Cleveland Clinic Center for Functional Medicine. His primary board certification is in family medicine through the American Board of Family Medicine (ABFM). The Institute for Functional Medicine (IFM) lists him as a certified practitioner, though IFM certification is a post-graduate training credential, not a state medical license or an American Board of Medical Specialties (ABMS) certification.

Consumers should confirm any physician's license independently through their state medical board. The Federation of State Medical Boards (FSMB) maintains a free public lookup tool at docinfo.org, and each state board publishes its own disciplinary records. This matters because telehealth companies can list prominent physicians as co-founders or advisors without those physicians directly supervising every order.

What IFM Certification Does and Does Not Confer

IFM certification documents completion of specific functional medicine coursework. It does not represent an ABMS-recognized specialty board, and the National Commission for Certifying Agencies (NCCA) does not accredit IFM's certification program. That does not make it worthless; it simply places it in the category of continuing medical education rather than primary specialty credentialing.

Operational Medical Staff

Beyond Dr. Hyman, Function Health employs or contracts with licensed physicians who sign laboratory orders in each state where the service operates. The company has not published a full roster of these physicians or their board certifications as of early 2025. Prospective subscribers should request the name and license number of the ordering physician in their state before enrolling.

How Function Health's Lab Model Works

Function Health does not operate its own laboratory. It routes orders to third-party reference labs, and those labs are subject to federal Clinical Laboratory Improvement Amendments (CLIA) oversight administered by the Centers for Medicare and Medicaid Services (CMS). CLIA regulations under 42 U.S.C. §263a require any lab that tests human specimens for diagnosis to hold a valid CLIA certificate. You can verify a lab's CLIA certificate through the CMS CLIA database.

CAP Accreditation and What It Means

The College of American Pathologists (CAP) offers an additional voluntary accreditation layer above the CLIA floor. CAP-accredited labs undergo on-site inspections every two years and must pass proficiency testing across all analyte categories they report. Quest Diagnostics and LabCorp, the two largest U.S. Reference networks and likely partners for services like Function Health, both hold CAP accreditation. Confirming which specific lab processes your sample is a reasonable due-diligence step, particularly for less common analytes.

Biomarker Panel Scope

The company advertises more than 100 biomarkers per annual draw. Standard panels include a comprehensive metabolic panel, CBC, lipid panel, thyroid function (TSH, free T3, free T4), sex hormones (testosterone, estradiol, SHBG, LH, FSH), inflammatory markers (hs-CRP, homocysteine), and select nutrient levels (vitamin D 25-OH, B12, ferritin). Many of these are standard-of-care tests with well-validated reference ranges established through decades of population data published in journals such as JAMA and The New England Journal of Medicine.

Certain "longevity" markers added to subscription panels, such as ApoB, Lp(a), and TMAO, have emerging but not yet fully standardized clinical decision thresholds. The 2022 ACC/AHA Cholesterol Guideline recommends ApoB as a secondary risk marker in select patients, which supports its inclusion. Lp(a) testing is similarly supported by European Society of Cardiology guidance. TMAO remains an area of active investigation; a 2017 review in JAMA Cardiology found associations with cardiovascular risk but noted that clinical utility is not yet established.

Regulatory Standing and Consumer Protection

CLIA and CMS Oversight

Any laboratory that processes human diagnostic specimens in the United States must hold a CLIA certificate issued by CMS. Direct-to-consumer lab ordering platforms are subject to state-level rules that vary considerably. Some states, including New York, Maryland, and New Jersey, restrict or prohibit direct-to-consumer lab orders without a licensed physician in the ordering loop. Function Health's model routes orders through affiliated physicians, which is designed to satisfy these requirements. Consumers in restricted states should verify compliance directly with the company before purchasing.

FDA Jurisdiction Over Lab-Developed Tests

The FDA has asserted jurisdiction over laboratory-developed tests (LDTs). In April 2024, the FDA finalized a rule phasing in oversight of LDTs as medical devices under 21 CFR Part 820. The FDA's LDT final rule applies to tests developed and performed in a single lab. Standard reference-lab assays from CAP/CLIA-certified labs generally use FDA-cleared or approved methods, which places them outside the LDT category. Subscribers should ask which analytes, if any, are run as lab-developed tests.

BBB Status

As of early 2025, Function Health does not appear as a BBB-accredited business on the Better Business Bureau national directory. Lack of BBB accreditation is not itself a disqualifying signal; accreditation is voluntary and fee-based. However, prospective subscribers can still search the BBB complaint database for any filed complaints regardless of accreditation status.

LegitScript Verification

LegitScript operates the primary third-party certification program that Google, Facebook, and major payment processors use to vet telehealth and pharmacy operators. As of early 2025, Function Health does not appear in LegitScript's verified merchant database. This is notable because many competing telehealth platforms have pursued LegitScript certification specifically to demonstrate compliance with federal prescribing and dispensing rules. The absence does not indicate illegality, but it does mean Function Health has not submitted to LegitScript's independent compliance review.

Evaluating Any Telehealth Lab Service: A Five-Point Credential Checklist

Before subscribing to Function Health or any comparable service, use the following verification steps.

Step 1. Verify Physician Licensure

Request the name and NPI number of the ordering physician for your state. Cross-check with FSMB DocInfo and your state medical board for active license status and disciplinary history. The NPI Registry confirms whether a provider holds a valid National Provider Identifier.

Step 2. Confirm Lab Accreditation

Ask which reference lab processes your samples. Verify their CLIA certificate through the CMS CLIA database and check for CAP accreditation at cap.org.

Step 3. Check State-Specific Direct-to-Consumer Lab Rules

The CDC's CLIA overview does not govern state consumer-protection rules. New York State Department of Health, for example, requires a licensed ordering provider for all clinical lab tests. Verify your state's rules independently.

Step 4. Review Biomarker Clinical Evidence

For each biomarker on a panel, check whether the U.S. Preventive Services Task Force (USPSTF) recommends routine screening for your age and risk group. The USPSTF grades evidence A through I; Grade I means insufficient evidence. Ordering tests with Grade I or no USPSTF recommendation does not mean they are harmful, but it does mean the clinical utility for asymptomatic individuals is unproven.

Step 5. Understand the Prescribing Pathway

If the service offers prescriptions (thyroid hormones, testosterone, metformin, or similar agents) based on lab results, confirm that a licensed physician with prescribing authority in your state reviews the results and that there is a documented physician-patient relationship. The DEA's telehealth prescribing regulations and state medical board telepractice standards both apply.

What Independent Medical Authorities Say About Routine Comprehensive Lab Panels

The USPSTF does not recommend comprehensive multipanel screening in asymptomatic adults as a single evidence-based package. Individual component recommendations exist. For example, the USPSTF recommends lipid screening for cardiovascular disease risk assessment, and the CDC recommends HbA1c or fasting glucose screening in adults aged 35 to 70 with overweight. However, the USPSTF has found insufficient evidence to recommend routine CBC, comprehensive metabolic panels, or hormone panels as population-wide asymptomatic screening tools.

A 2019 systematic review in BMJ examining general health checks found no significant reduction in all-cause mortality (relative risk 0.99, 95% CI 0.95 to 1.03, across 17 trials). Ordering many tests increases the statistical probability of false-positive results. With 100 independent tests at a 95% specificity threshold, the probability of at least one false positive in a healthy individual approaches 99.4% by basic probability theory. This is not a reason to avoid all lab testing; it is a reason to interpret results within a clinical context provided by a physician who knows your full history.

The American College of Physicians (ACP) guidance on diagnostic testing states: "Physicians should choose tests based on the pretest probability of disease and the test characteristics, not simply because the test is available."

A 2021 paper in JAMA Internal Medicine quantified the downstream cascade triggered by incidental findings on broad screening panels. The study found that one incidental finding requiring follow-up occurred in approximately 38% of asymptomatic adults undergoing expanded lab panels, generating additional imaging, specialist visits, and procedural costs without demonstrable mortality benefit.

Common Complaints and How to Evaluate Them

Result Interpretation Without Clinical Context

The most frequent complaint category for direct-to-consumer lab services involves receiving abnormal flags without adequate clinical interpretation. Function Health provides algorithmic interpretation tools and physician review, but the depth of that review, whether it is a cursory automated flag or a substantive individualized assessment, is not publicly detailed. Any result flagged outside of reference range warrants follow-up with a primary care physician who has access to your full medical history, medication list, and physical examination findings.

Physician Availability for Follow-Up

Subscription lab services typically do not offer ongoing physician-patient relationships equivalent to a primary care practice. The American Academy of Family Physicians (AAFP) recommends that telehealth encounters include clear documentation of the provider-patient relationship and pathways for follow-up care. Subscribers should ask specifically: what happens if a result requires urgent clinical action, and which physician is responsible for that communication?

Data Privacy

Lab results are protected health information under HIPAA. HHS Office for Civil Rights enforces the HIPAA Privacy Rule for covered entities and business associates. Consumers should review Function Health's privacy policy and business associate agreement structure to confirm HIPAA-compliant data handling before submitting specimens.

How Function Health Compares to Standard-of-Care Lab Ordering

A conventional primary care physician orders labs based on clinical indication, age-appropriate screening guidelines, and shared decision-making with the patient. The American College of Preventive Medicine and USPSTF publish specific age- and sex-based recommendations for which tests carry Grade A or B evidence in asymptomatic populations.

Function Health's model differs in three specific ways. First, it bundles tests regardless of individual clinical indication. Second, it operates without a preceding physical examination. Third, it charges a flat subscription fee rather than billing insurance, which means all costs fall to the consumer out of pocket.

The AHA's 2021 cardiovascular prevention guideline supports ApoB measurement in patients with borderline cardiovascular risk (10-year ASCVD risk 7.5% to 20%). For a 28-year-old with no risk factors, ordering ApoB carries no guideline support. Function Health's panel orders it regardless of baseline risk, which may produce actionable results in some patients and unnecessary anxiety in others.

The Endocrine Society Clinical Practice Guideline on testosterone therapy recommends testosterone measurement only in men with signs and symptoms of hypogonadism, not as routine screening. Ordering testosterone in asymptomatic men may detect low-normal values that do not meet diagnostic criteria for hypogonadism but may nonetheless prompt patients to seek treatment.

Specific Data Points Consumers Should Request From Function Health

Before enrolling, ask the company for the following in writing:

• The name, NPI, and state medical license number of the physician who will sign your lab orders
• The name and CLIA certificate number of the reference lab processing your samples
• Whether any analytes on the panel are run as lab-developed tests subject to the FDA's 2024 LDT rule
• The specific physician review process: how many minutes, by whom, and what credentials that reviewer holds
• The escalation protocol if a result indicates a value requiring urgent clinical attention, such as a glucose above 400 mg/dL or a TSH below 0.01 mIU/L

These are standard disclosure requests. Any legitimate medical service should answer them without hesitation. A company unwilling to provide physician NPI numbers or CLIA certificates is a company worth reconsidering.

The FDA's guidance on consumer questions about lab tests notes that consumers have the right to receive clear information about who ordered their test, which lab performed it, and what oversight framework governs accuracy. Invoking that guidance in writing to a telehealth company is a reasonable consumer-protection step.